T2 Biosystems
Founded Year
2006Stage
IPO | IPOTotal Raised
$96.24MDate of IPO
8/7/2014Market Cap
0.09BStock Price
0.28
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
T2 Biosystems Patents
T2 Biosystems has filed 75 patents.
The 3 most popular patent topics include:
- Molecular biology
- Biotechnology
- Blood tests
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/21/2019 | 6/6/2023 | Laboratory equipment, Molecular biology, Cell biology, Blood tests, Biotechnology | Grant |
Application Date | 10/21/2019 |
|---|---|
Grant Date | 6/6/2023 |
Title | |
Related Topics | Laboratory equipment, Molecular biology, Cell biology, Blood tests, Biotechnology |
Status | Grant |
Latest T2 Biosystems News
Sep 15, 2023
September 15, 2023 16:05 ET Lexington, Massachusetts, UNITED STATES LEXINGTON, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on September 7, 2023, under the T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted on March 1, 2018 and amended and restated on February 16, 2023 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of three option grant awards to purchase an aggregate of 1,200 shares of T2 Biosystems common stock and one grant of restricted stock units ("RSUs") covering 40,000 shares of the Company’s common stock granted to the Company’s Vice President of Regulatory Affairs, Scott Blood. The exercise price of the options was $0.3430 which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on September 7, 2023. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. Subject to Mr. Blood’s continued service to the Company, one third of the RSUs shall vest on each of the first two anniversaries of the grant date and the remainder shall vest on the third anniversary of the grant date. The stock options and the RSU’s each have a ten-year term. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4). About T2 Biosystems: T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2CaurisTM Panel, and T2Lyme TM Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens. Investor Contact:
T2 Biosystems Frequently Asked Questions (FAQ)
When was T2 Biosystems founded?
T2 Biosystems was founded in 2006.
Where is T2 Biosystems's headquarters?
T2 Biosystems's headquarters is located at 91 Hartwell Avenue, Lexington.
What is T2 Biosystems's latest funding round?
T2 Biosystems's latest funding round is IPO.
How much did T2 Biosystems raise?
T2 Biosystems raised a total of $96.24M.
Who are the investors of T2 Biosystems?
Investors of T2 Biosystems include Flybridge Capital Partners, Polaris Partners, Flagship Pioneering, Partners Innovation Fund, Arcus Ventures and 11 more.
Who are T2 Biosystems's competitors?
Competitors of T2 Biosystems include Novus Diagnostics, Akonni Biosystems, iMMCO Diagnostics, Esaote, Advanced Cell Diagnostics and 14 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare T2 Biosystems to Competitors
Gold Standard Diagnostics (GSD) provides diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.
Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.
Clinical Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.
BMDSys develops, produces, sells and services non-invasive, contact-free cardiac diagnostic imaging systems using extremely high sensitive magnetic sensors. It does not expose the patient to any X-Rays, magnetic field or any other kind
ViralTest offers molecular-based diagnostics development for niche infectious diseases markets.
BioMicro Systems was founded in 2000 to develop and improve microfluidic microarray sample processing. Microarrays are tools used by major pharmaceutical companies and research laboratories to sift through and analyze information contained within a genome. A microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or microsphere-sized beads. In 2003 BioMicro Systems launched the MAUI Hybridization System, a cutting-edge microarray instrument, designed to target the processing bottleneck encountered during the critical hybridization step in gene expression studies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
